Figure 2. Differences in epigenetic aging between older breast cancer survivors and non-cancer controls at the first blood sample, approximately 24- to 36-months after enrollment (which was pre-systemic therapy for survivors).

Point estimates for differences in (a) adjusted epigenetic age and (b) adjusted Dunedin Pace of Aging (DunedinPACE) at the first blood sample for all survivors (n=89), as well as survivors who received chemotherapy (without or without hormonal therapy; n=29) or hormonal therapy alone (n=51), relative to matched non-cancer controls (n=101) at the first blood sample. Models adjusted for chronological age at the first blood sample and comorbidities. Error bars represent 95% confidence intervals for each point estimate. **p<.01, *p<.05.